

Index

- α 1-antitrypsin, 19
- α -methyl dopa, impact on anaesthesia, 190
- α -fetoprotein, 86
- abruption, *see* placental abruption
- access to antenatal care, 10
- access to laboratory facilities, 47
- accuracy of BPM devices, 5
- ACE inhibitors, 143
- acidosis, compensatory metabolic, 191
- activated protein C, 143
- active management, *see* interventionist care
- acute renal failure, 68
- ADAM-12 as part of multivariable analysis, 89, 90
- adverse conditions of pre-eclampsia, 39
- age,
 - as a risk factor, 78
 - maternal, pre-eclampsia risk, 39
 - paternal, 81
 - see also* gestational age
- aggressive management, *see* interventionist care
- aggressiveness, 144
- airway,
 - difficult, 196
 - examination at initial assessment, 187
- albumin, 19
 - pre-eclampsia risk, 39
- albuminuria, 22
- alcohol, 101, 123
- alfentanil, 197
- alkalosis, respiratory, 191
- ALT,
 - serum levels, 43
 - timing of delivery, 171
- ambulance services, 126
- ambulatory blood pressure measurement, 6
 - use in community, 3
 - vs. HBPM, 7
- anaesthesia, 185–207
 - awareness during, 201
 - blood pressure monitoring after, 190
 - central venous catheters, 191
 - delayed complications, 201
 - difficult airway, 196
 - dural puncture, 201
 - early assessment, 185
 - early complications, 201
 - early warning systems, 190
 - for Caesarean delivery, 196, 395–9
 - general anaesthesia, 196
 - GRADE evaluation of best practice points, 400
 - haemodynamic management, 197
 - hypertensive response to intubation, 196
 - initial assessment, 186
 - international guidelines on recommendations for, 402–5
 - intravenous bolus of crystalloid, 198
 - local anaesthetic infiltration, 200
 - minimally invasive cardiac output monitoring devices, 191
 - monitoring for, 187
 - non-depolarising muscle relaxants, 197
 - pharmacological agents used in pre-eclampsia and, 190
 - post-traumatic stress disorder after, 201
 - postoperative complications, 202
 - postpartum issues, 201
 - prevention of hypertensive response to intubation, 393
 - priorities for, 206
 - prolonged neuromuscular block, 197
 - resuscitation equipment, 185
 - systemic effects of pre-eclampsia on, 188–9
 - transthoracic echocardiography, 191
 - use of vasopressors, 198
- analgesia,
 - fetal well-being and, 191
 - in labour, 191
 - inhalation, 192
 - intravenous, 203
 - methods for, 186
 - neuraxial, 204
 - oral, 203
 - pain-induced sympathetic response and hypertension, 191
 - parenteral, 192
 - patient-controlled, 193
 - rectal, 203
 - WHO analgesic ladder, 203
 - wound infiltration, 204
- angiogenic factor imbalance, 36, 86, 44
 - future research priorities, 52
 - pre-eclampsia definition and, 37

- angiogenic factor imbalance *continued*
 - with circulating proteins, 90
- angiotensin receptor blockers, 143
- antenatal care,
 - access to, 10
 - attendance at, 9
 - development of surveillance, 76
 - first trimester ultrasound, 168
 - health care worker staffing levels for, 9
 - late presentation for, 47
 - number of visits, 8
 - pre-eclampsia prevention and low rates of, 110
 - recommended components of, 9
 - Scottish paradigm, 33
 - screening for proteinuria, 20
 - timing of initiation, 9
- antiangiogenic factors, 86
- antihypertensives,
 - choice of agent, 136, 141
 - commonly used agents, 142
 - for pre-eclampsia prevention, 105, 316
 - GRADE evaluation of best practice points, 365–7
 - in non-severe hypertension, 140–4
 - in severe hypertension, 135–40
 - international clinical guidelines, 155, 370–81
 - maternal outcomes after use, 142
 - maternal side-effects, 143
 - policy briefs, 368
 - treatment wall chart, 349
 - use during breastfeeding, 140
- antioxidants, 103
- antiphospholipid syndrome, 79,
- antiphospholipid antibody syndrome, 43
- antithrombin, 148, 150
- antithrombin III deficiency, 79
- anxiety, 82
- aspirin, 292, 318–321
 - impact on anaesthesia, 190
 - low-dose,
 - and hypertensive disorders in pregnancy, 102
 - combined with calcium supplementation, 106
 - for pre-eclampsia prevention, 102, 105
 - use in under-resourced settings, 110
- assisted reproductive treatment, as a risk factor, 81
- AST, serum levels, 43
- asthma, 136, 141
- atenolol, 143
 - paediatric neurodevelopment and, 143
- attendance at antenatal care, 9
- audit of practice, 150
- auscultatory methods of blood pressure measurement, 4
- automated blood pressure measurement devices, 5
- automated testing of urinary dipsticks, 22
- awareness, during anaesthesia, 201
- β -lipoprotein, 19
- bariatric surgery for obesity, 224
- bed rest, 109, 125
- behaviour and paediatric neurodevelopment, 218
- best practice points,
 - antihypertensives
 - in non-severe hypertension, 152
 - in severe hypertension, 152
 - blood pressure measurement, 11
 - care beyond 6 weeks after birth, 225
 - care in 6 weeks after birth, 224
 - diagnosis of hypertension, 11
 - fluids, 152
 - for anaesthesia and analgesia, 205
 - for classification of pre-eclampsia, 46
 - for diet lifestyle and place of care, 128
 - for fluids drugs and transfusions, 365–7
 - for risk factors and predictors, 91
 - GRADE evaluation
 - for anaesthesia, 400
 - for classification of hypertensive disorders of pregnancy, 255–6
 - for diet, 345
 - for hypertension, 236–7
 - for lifestyle, 345
 - for mode of delivery, 383
 - for place of care, 345
 - for postpartum care, 410
 - for preventing pre-eclampsia, 340–3
 - for proteinuria, 250
 - for timing of delivery, 383
 - in proteinuria, 27
 - mode of delivery, 177
 - place of delivery, 176
 - prevention of pre-eclampsia in low-risk women, 112
 - prevention of pre-eclampsia in women at increased risk, 113
 - timing of delivery, 176, 177
- beta blockers, 141
 - use with methyldopa, 142
- betamethasone, 176
- biomarkers,
 - for pre-eclampsia, 44
 - future research priorities, 51
 - in multivariable prediction analyses, 88
 - in univariable prediction analyses, 86, 87
- birth weight, maternal, 79
 - see also large for gestational age, small for gestational age
- blindness, 68
- blood film, for pre-eclampsia, 42
- blood pressure,
 - access to monitoring facilities, 47
 - as a predictor, 83
 - changes with gestational age, 1, 2

- changes with parity, 2
- chocolate and, 103
- circadian rhythm, 1
- importance of repeat measurement, 2
- in offspring after pre-eclampsia, 218
- invasive monitoring, 198
- maintenance in anaesthesia, 197
- monitoring after anaesthesia, 190
- timing of delivery, 171
- with uterine artery PI as predictor, 89
- blood pressure measurement,
 - ABPM, 6
 - accuracy of devices, 5
 - aneroid devices, 5
 - auscultatory methods, 4
 - automated devices, 4
 - choice of device during pregnancy, 5
 - choice of device for setting, 5, 6
 - comparison of ABPM and HBPM, 7
 - cuff size for, 3, 240
 - HBPM, 6
 - importance of repeat, 2
 - in the community, 3
 - in under-resourced settings, 7–10
 - international guidelines, 240–6
 - position for, 3
 - recalibration of devices, 5
 - sample policy brief, 238
 - settings, health facility, 5
 - smartphone and tablet technologies, 8
 - solar-powered devices, 8
 - techniques for, 3–7
- body mass index,
 - pre-eclampsia risk, 40
 - pre-pregnancy, 79
- bradycardia,
 - fetal, 195
 - neonatal, 136, 137
- brain natriuretic peptide, 52
- breastfeeding,
 - antihypertensive use during, 140
 - hypertension management and, 216
- bronchopulmonary dysplasia, 69
 - after vaginal cf Caesarean delivery, 175
- bupivacaine-soaked sponges, 204

- C-reactive protein, 86
- Caesarean section,
 - after MgSO₄ use, 145
 - anaesthesia for, 196, 395–9
 - at 37⁺⁰–42⁺⁰ weeks
 - bronchopulmonary dysplasia and, 175
 - choice of anaesthesia for, 199
 - combined spinal–epidural for, 200
 - epidural anaesthesia for, 200
 - local anaesthetic infiltration, 200
 - postoperative pain management, 202–4
 - principles for anaesthetic management for, 197
 - spinal anaesthesia for, 200
 - spinal vs. epidural, 199
 - spinal vs. general, 199
 - uterine rupture after, 175
- calcium, 292–295, 322
- calcium: creatinine ratio, 84
- calcium channel blockers, 136, 137, 141
- calcium gluconate, antidote to MgSO₄, 197
- calcium supplementation, 75
 - combined with low-dose aspirin, 106
 - for pre-eclampsia prevention, 102, 105
 - use in under-resourced settings, 110
- captopril, 139, 140
- carboprost, impact on anaesthesia, 190
- cardiac output monitoring devices, 191
- cardiovascular disease,
 - antihypertensive use and, 141
 - paternal, 81
 - risk, 35
 - risk factors after pre-eclampsia, 218, 219
- catastrophic antiphospholipid antibody syndrome, 43
- catecholamine release, 191
- central nervous system,
 - proteinuria and, 20
 - white matter lesions, 221
- central venous catheters, 191
- cerebral palsy, 146
- cerebrovascular disease, 35
- cervix,
 - ripening of, 175
 - unfavourable, 174, 175
- chest pain, 171
- CHIPS (Control of Hypertension in Pregnancy Study), 140
- chlamydia, 81
- chlorpromazine promethazine pethidine, cf MgSO₄, 144
- chocolate, higher intake lowers blood pressure, 103
- chronic hypertension, 33
 - as a risk factor, 79
 - estimates for incidence, 64
 - renal disease, 187
 - see also* pre-existing hypertension
 - temporal trends in, 65
 - timing of delivery in, 174
- chronic kidney disease, 79
- circadian rhythm of blood pressure, 1
- circulating proteins, 90
- climate and pre-eclampsia trends, 66
- CLIP (Community-Level Interventions for Pre-eclampsia) trial, 64, 127
- clonidine, 139, 140
- co-enzyme Q10 supplementation, 107, 109

- coagulation,
 - neuraxial analgesia and, 194
 - tests for pre-eclampsia, 42
- coagulopathy, 176
- communication,
 - doctor–patient, 45
 - with patient, 46
- community,
 - blood pressure measurement in, 3
 - postpartum care, 226
- community engagement, 127
- community-based care, 126
- comorbidity,
 - commonly linked to gestational hypertension, 187
 - in hypertension, 34
- compensatory metabolic acidosis, 191
- complete blood count, 42
- congenital malformations, 81
- congestive cardiac disease and proteinuria, 20
- Congo red dot test, 28
- connective tissue disorders, 187
- continuous spinal analgesia, 195
- copper, 105, 109
- corticosteroids,
 - antenatal, 176
 - for fetal lung maturity, 168
 - use in expectant care, 169
 - use in HELLP syndrome, 148
- cost-effectiveness,
 - of interventionist care, 174
 - of MgSO₄, 144, 145
 - of prediction, 92
 - of proteinuria testing, 26
- counselling,
 - for expectant vs. interventionist care, 169
 - nutritional education, 102
- CRADLE BP device, 235
- creatinine,
 - calcium: creatinine ratio, 84
 - IPG: creatinine ratio, 84
 - pre-eclampsia risk, 40
 - serum levels, 43
 - timing of delivery, 171
- crystalloid, intravenous bolus, 198
- cuff,
 - correct position, 3
 - correct size, 3
 - importance in anaesthesia, 198

- dalteparin, 108
- DASH (dietary approached to stop hypertension) diet, 107, 124
- definitions,
 - bed rest, 109, 125
 - HELLP syndrome, 38
 - hypertension, 1
 - pre-eclampsia, 37, 266–73
 - severe hypertension, 2
 - severe pre-eclampsia, 266–73
 - significant proteinuria, 26
 - systolic and diastolic criteria, 2
- delivery,
 - indications for in pre-eclampsia, 169, 169
 - see also* Caesarean section; vaginal delivery
 - timing and mode, 167–79
- demographic risk factors, 78
- depression, 82
- dexamethasone, 148, 176
- diabetes, 78, 79
 - antihypertensive use and, 141
 - as a risk factor, 79
 - chronic hypertension, 187
 - pre-gestational, 79
 - risk after pre-eclampsia, 220
- diabetic nephropathy, 79
 - antihypertensive use and, 141
- diamorphine, 193
- diazepam, cf MgSO₄, 144
- diazoxide, 137, 140
- diet,
 - GRADE evaluation for best practice points, 345
 - international guidelines for recommendations, 346–8
 - modifications recommended for all women, 223
 - role in pre-eclampsia, 123–4
 - weight loss in obesity, 123
- dietary changes, 123, 294–299
 - for pre-eclampsia prevention, 102, 107, 322–325
 - salt restriction, 102
- difficult airway, 187, 196
- dipsticks,
 - for spot albumin: creatinine ratio, 25
 - urinary, 21
- diuretics, 104, 142, 308, 332
- dopamine, renal dose, 135
- Doppler,
 - fetal status and delivery, 175
 - ophthalmic artery, 40
 - uterine artery, 40, 84
 - velocimetry, 43
 - with angiogenic imbalance measures, 45
- ductus venosus, 45
- dural puncture, 201
- dyspnoea, 171

- early delivery, *see* interventionist care
- early warning systems, 190
 - response triggering parameters in, 192
- eclampsia,
 - incidence estimates, 68
 - MgSO₄ use for, 144

- prevention, 145, 146
- thrombocytopaenia, 189
- 'eclampsia box', 151
- education,
 - nutritional counselling, 102
 - of health care providers, 221
 - of women, 46, 221
 - pre-eclampsia prevention and low rates of, 110
 - strengthening pre-eclampsia knowledge in women, 49
- EmONC, 169
- end tidal CO₂ monitoring, 191
- end-diastolic flow in umbilical artery, 45
- end-organ function,
 - complications, 135
 - pre-existing hypertension, 215
- endothelial dysfunction tests, 86
- endothelial-platelet interactions, 86
- endotheliosis, glomerular, 19
- EOST (Emergency Obstetric Simulation Training), 151, 351–64
- ephedrine, 198
- epidemiology, 63–9
- epidural analgesia, 193
 - combined spinal-epidural, 194
 - continuous spinal analgesia, 195
 - vs. parenteral, 193
 - vs. spinal in pre-eclampsia, 199
- epigenome, 51
- epinephrine, 200
- equipment,
 - availability and choice of care level, 169
 - availability and use of local anaesthetic infiltration for Caesarean section, 200
 - availability in under-resourced settings, 7
 - early warning tool, 7
 - essential equipment for resuscitation, 186
 - for fetal monitoring, 186
 - see also* devices
 - semi-automated, 7
- ergometrine, 176
 - contraindicated in pre-eclampsia, 201
 - impact on anaesthesia, 190
- ESMOE (Essential Steps in Managing Obstetric Emergencies), 151, 351–64
- esomeprazole, 148, 150
- ethnicity, 141
 - as a risk factor, 78
- evidence-based care in under-resourced setting, 150
- exercise,
 - and risk, 82
 - pre-eclampsia prevention and, 103, 109
 - proteinuria and, 20
 - role in pre-eclampsia, 124
 - stretching, 109
 - use in under-resourced settings, 111
 - walking, 109
- expectant care,
 - at 24⁺⁰–33⁺⁶ weeks, 173
 - at 34⁺⁰–36⁺⁶ weeks, 173
 - at <24⁺⁰ weeks, 172
 - counselling, 169
 - health care system and, 169
 - of HELLP syndrome, 65
 - risks of, 169
 - vs. interventionist care, 168
- externalising behaviour, 144
- factor V Leiden mutation, 79
- familial risk factors, 76–8
- fentanyl, 197
- fetal distress, 136
- fetal growth,
 - antihypertensives and, 143
 - restriction, 69
- fetal heart pattern, 141
- fetal heart rate, 141
 - monitoring, 136
- fetal lung maturity and corticosteroid use, 168, 169, 176
- fetal monitoring, 186
 - in pre-eclampsia, 45
- fetal neuroprotection, 146
- fetal testing for pre-eclampsia, 43
- fetal well-being and analgesia, 191
- fetotoxic agents, 143
- fever and proteinuria, 20
- fibrinogen for pre-eclampsia, 42
- fibronectin, 86
 - glycosylated, 45
- flavonoids, 103
- fluid management,
 - GRADE evaluation of best practice points, 365–7
 - in pre-eclampsia, 133–5
 - international guidelines, 155, 370–81
 - restriction in pre-eclampsia, 135
- folate supplementation, 105
- folate-containing multivitamins, 107
 - pre-eclampsia prevention and, 103
 - use in under-resourced settings, 111
- fullPIERS model, 39, 68
 - timing of delivery, 171
- furosemide, 135
- garlic supplementation, 105, 107, 113
- gender, fetal, as a risk factor, 81
- general anaesthesia, 145, 196
 - vs. spinal in pre-eclampsia, 199
- genetics,
 - familial risk factors for pre-eclampsia, 76
 - maternal risk factors, 77
 - paternal risk factors, 78

- genetics *continued*
 - thrombophilias, 79
- gestational age,
 - assessment of, 168
 - in under-resourced settings, 168
 - methods for, 168
 - at diagnosis and timing of delivery, 170
 - blood pressure changes with, 1, 2
 - mode of delivery and, 175
 - stillbirth and, 69
 - timing of delivery, 167, 171
 - at <24⁺⁰ weeks, 172
 - at 24⁺⁰–33⁺⁶ weeks, 172
 - at 34⁺⁰–36⁺⁶ weeks, 173
 - at 37⁺⁰–42⁺⁰ weeks, 174
- gestational hypertension,
 - classification, 34
 - definition, 35
 - estimates for incidence, 64
 - previous, as a risk factor, 80
 - progression to pre-eclampsia, 67
 - work up after, 216
- glomerular endotheliosis, 19
- glomerular proteins, 19
- glucose serum levels, 43
- GRADE evaluation for best practice points,
 - classification of hypertensive disorders of pregnancy, 255–6
 - for anaesthesia, 400
 - for diet, 345
 - for fluids drugs and transfusions, 365–7
 - for hypertension, 236–7
 - for lifestyle, 345
 - for mode of delivery, 383
 - for place of care, 345
 - for postpartum care, 410
 - for preventing pre-eclampsia, 340–3
 - for proteinuria, 250
 - for timing of delivery, 383
- gross motor function, 144
- group B streptococci, 81

- haematoma, spinal, 202
- haemodynamic management, 197
- haemoglobin for pre-eclampsia diagnosis, 42
- haemorrhage,
 - potential for, 176
 - risk, 76
- HBPM (home blood pressure monitoring), 6
 - comprehensive list, 5
 - use in community, 3
 - vs. ABPM, 7
- headache,
 - postdural puncture headache, 195, 200, 201
 - pre-eclampsia risk, 39
 - timing of delivery, 171
- health care workers,
 - education of, 221
 - knowledge translation tools, 409
 - pre-eclampsia prevention and training, 110
 - self-help training, 151
 - shortage of, 67, 92
 - staffing levels, 9
 - training for blood pressure measurement, 235
 - training material for, 407–8
- health facility, blood pressure measurement in, 5
- heart-healthy diet, 107
- heat coagulation test, 22
 - example, 24
 - interpretation, 23
- height, 79
- HELLP syndrome,
 - corticosteroids for, 148
 - definition, 38
 - estimates for incidence, 65
 - ethnicity and, 78
 - expectant management, 65
 - imitators, 148
 - international guidelines for therapy, 156
 - level of care required, 169
 - management at 24⁺⁰–33⁺⁶ weeks, 173
 - postpartum appearance, 216
 - therapies for, 147–8, 153
 - transfusion for, 147
- heparin, 148
 - for pre-eclampsia prevention, 107, 323
- hepatic haematoma, 68
- hepatic rupture, 68
- high-sensitivity C-reactive protein, 86
- histidine-rich glycoprotein, 90
- HIV, 81
- home care, 125
- hospital day units, 125
- human chorionic gonadotrophin, 86, 88, 89
 - as part of multivariable analysis, 88, 89
- hydralazine, 136, 138, 143
 - impact on anaesthesia, 190
- hydration, 123
- hyperlipidaemia, 79
- hypertension,
 - best practice points, 236
 - chronic, 33
 - classification of disorders of pregnancy, 34
 - definition, 1
 - diagnosis, international guidelines, 240–6
 - hypertensive response to intubation, 196
 - mean arterial pressure, 3
 - measurement of, 1–13
 - pain-induced sympathetic response, 191
 - postpartum appearance, 215
 - postpartum treatment, 215

- refractory, 140
- risk after pre-eclampsia, 219
- severe,
 - antihypertensive treatment, 135
 - definition, 2
 - treatment wall chart, 349
- hypertensive disorders of pregnancy,
 - abstention from alcohol and, 101
 - associated morbidity and mortality, 66
 - calcium supplementation, 102
 - classification, 33–53
 - common comorbidities, 187
 - epidemiology, 63–9
 - estimates on incidence, 63
 - folate-containing multivitamins, 103
 - GRADE evaluation for best practice points, 255–6
 - international guidelines on classification, 257–65
 - lifestyle changes, 103
 - low-dose aspirin, 102
 - management of, 154
 - non-pharmacological management, 129
 - risk factors for, 66
 - timing and mode of delivery, 167–79
- hypertensive emergency, 135
- hypertensive response to intubation, 196, 393
- hypertensive urgency, 135
- HYPITAT trial, 40
- HYPITAT II trial, 173, 174
- hypotension, 188
 - avoidance of, 198
 - neuraxial anaesthesia and, 198
 - spinal analgesia and, 195
- hypothyroidism, risk after pre-eclampsia, 220

- ICU, refractory hypertension in, 140
- immigrant status,
 - pre-eclampsia risk, 39
 - pre-eclampsia trends and, 66
- immune thrombocytopenia, pre-existing hypertension and, 41
- immunoglobulins, 19
- immunosuppression, 44
- inattention, 144
- incidence,
 - chronic hypertension, 64
 - estimates, 63
 - gestational hypertension, 64
 - in HIC, 64
 - in LMIC, 64
 - late-onset vs. early-onset, 65
 - pre-eclampsia, 64
 - temporal trends in, 65
- indwelling spinal catheter, 195
- infection,
 - as a risk factor, 81
 - treatment of for pre-eclampsia prevention, 110
- information provision to patient, 46
 - see also* education
- inhalation analgesia, 192
- inhibin, 86
- inositol phosphoglycan-P, 84
- interferon- γ , 45
- international guidelines,
 - classification of hypertensive disorders of pregnancy, 257–65
 - for anaesthesia and analgesia, 205
 - for classification of pre-eclampsia, 50
 - for diet, lifestyle and place of care, 129
 - for fluid, drugs and transfusions, 155
 - for pre-eclampsia prediction, 288–9
 - for prevention of pre-eclampsia, 113
 - for risk factors and predictors, 91
 - hypertension identification, 12
 - in proteinuria, 28
 - mode of delivery, 179, 385–392
 - postpartum care, 227
 - recommendations,
 - for anaesthesia, 402–5
 - for blood pressure measurement and diagnosis, 240–6
 - for fluids drugs and transfusions, 370–81
 - for postpartum care, 414–19
 - for proteinuria diagnosis, 251–3
 - on diet, 346–8
 - on lifestyle, 346–8
 - on place of care, 346–8
 - timing of delivery, 178, 385–92
- interventionist care,
 - at 24⁺⁰–33⁺⁶ weeks, 172
 - at 34⁺⁰–36⁺⁶ weeks, 173
 - cost-effectiveness of, 174
 - counselling, 169
 - vs. expectant, 168, 173
- intracerebral haemorrhage and proteinuria, 20
- intracervical Foley balloon, 175
- intrathecal catheter, 195
- intrathecal morphine, 204
- intrauterine growth restriction, 36, 45
 - diagnosis, 168
 - early-onset, 150
 - induction of labour and, 175
- intubation,
 - hypertensive response to, 196
 - prevention of, 393
- iodine, 105, 109
- IPG: creatinine ratio, 84
- iron, 109
- iron supplements, 105
- ischaemic heart disease risk after pre-eclampsia, 219
- isradipine, 137

THE FIGO TEXTBOOK OF PREGNANCY HYPERTENSION

- ketamine, 203
- ketanserin, 137
- knowledge translation tools, 409

- L-arginine, 148, 149
 - for pre-eclampsia prevention, 108, 336
- labetalol, 135, 136, 138, 139, 141, 142
 - hypertensive response to intubation, 197
 - impact on anaesthesia, 190
 - paediatric neurodevelopment and, 143
- laboratory markers, 85
- labour induction, 175
 - in women with gestational hypertension, 174
- lactate dehydrogenase, serum levels, 43
- large for gestational age, risk in pre-eclampsia, 35
- last menstrual period,
 - assessment of gestational age, 168
 - memory aids for, 168
- leptin, 45
- lidocaine, 200
- lifestyle,
 - changes, 312
 - changes for cardiovascular risk, 223
 - changes for pre-eclampsia prevention, 103, 108, 326
 - GRADE evaluation for best practice points, 345
 - international guidelines for recommendations, 346–8
 - modifications recommended for all women, 223
 - role in pre-eclampsia, 124
 - use in under-resourced settings, 112
- literature searches, 275–6
- LMICs, *see* under-resourced settings
- long-term paediatric neurodevelopment, 143
- low-dose aspirin, 75
- low-molecular-weight heparin, 107, 108
 - use in under-resourced settings, 112
- lupus nephropathy, 79

- magnesium sulphate, 137
 - analgesic effect, 203
 - antihypertensives in non-severe hypertension, 153
 - Caesarean delivery after, 145
 - contraindication for non-depolarising muscle relaxants, 197
 - cost-effectiveness, 144, 145
 - dose reduction, 145
 - for eclampsia treatment, 144
 - for pre-eclampsia treatment, 144
 - impact on anaesthesia, 190
 - implications for anaesthesia, 187
 - international guidelines, 156
 - intramuscular administration, 350
 - obesity and dose required, 146
 - policy brief, 369
 - treatment wall chart, 350
 - use in expectant care, 169
- magnesium supplementation, 103, 109
- malaria, 81
- Malawi Demographic Health Survey, equipment availability, 7
- MAP (mean arterial pressure), 3, 88, 89
 - as part of multivariable analysis, 89
- masked hypertension, 34, 40
- maternal birth weight, 79
- maternal placental syndrome, 220
- mean arterial pressure in hypertension in pregnancy, 3, 88, 89
- measurements,
 - importance of repeat blood pressure measurements, 2
 - of hypertension, 1–13
 - of proteinuria, 19–29
- medical history,
 - as a risk factor, 79
 - paternal, 81
- medullary sponge kidney, 142
- memory aids for remembering last menstrual period, 168
- meningitis, 202
- mental health,
 - as a risk factor, 82
 - risks after pre-eclampsia, 221
- MEOWS (Modified Early Obstetric Warning Systems), 191
- mercury sphygmomanometer, 5
- metformin, for pre-eclampsia prevention, 109
- methyldopa, 137, 139, 141
 - paediatric neurodevelopment and, 143
 - use of, 142
- Microlife 3AS1-2 hand-held device, 10, 235
- micronutrients, 298–303
 - deficiencies and risk, 82
 - for pre-eclampsia prevention, 103, 109, 328
- minimally invasive cardiac output monitoring devices, 191
- miniPIERS model, 48, 68
 - timing of delivery, 171
- miscarriage, previous, as a risk factor, 80
- misoprostol, 175
 - impact on anaesthesia, 190
- mode of delivery,
 - at 34⁺⁰–36⁺⁶ weeks, 174
 - choice of, 175–6
 - priorities for, 178
 - see also* Caesarean section; vaginal delivery
- monitoring for anaesthesia, 187
- morbidity,
 - associated with hypertensive disorders of pregnancy, 66
 - early anaesthetic assessment and reduction in, 185
 - excess in interventionist care at 24⁺⁰–33⁺⁶ weeks, 172

- interventionist care and, 173
- maternal,
 - associated with hypertensive disorders of pregnancy, 66
 - rates of, 68
 - timing of delivery at 34⁺⁰–36⁺⁶ weeks, 173
- neonatal,
 - respiratory, 173
 - timing of delivery at 34⁺⁰–36⁺⁶ weeks, 173
- perinatal, 69
- mortality,
 - in LMICs, 66
 - maternal,
 - associated with hypertensive disorders of pregnancy, 66
 - rate in Sri Lanka, 49
 - rate in UK, 48
 - neonatal, 69
 - perinatal, 69
- MTHFR single nucleotide polymorphism, 79
- multiple pregnancy,
 - as a risk factor, 80
 - pre-eclampsia risk, 39
- multivitamins, folate-containing, 107
- myocardial infarction, markers for, 52

- near-miss morbidity, 67
- neonatal bradycardia, 136, 137
- neonatal death, 69
- nephropathy,
 - diabetic, 79
 - lupus, 79
- nerve damage after neuraxial analgesia, 202
- neuraxial analgesia,
 - cf parenteral, 193
 - choice of route in pre-eclampsia, 199
 - combined spinal–epidural for, 194, 200
 - contraindications, 193
 - epidural, 193
 - for Caesarean section, 199, 200
 - hypotension and, 198
 - neuroanatomy for needle placement, 187
 - postoperative, 204
 - postoperative complications, 202
 - single-shot spinal analgesia, 195
- neurodevelopment,
 - long-term, 143
 - paediatric, 217
- neuroprotection, 146
- neutrophil gelatinase-associated lipocalin, 45
- nifedipine, 136, 138, 141
 - hypertensive response to intubation, 197
 - impact on anaesthesia, 190
 - implications for anaesthesia, 187
 - paediatric neurodevelopment and, 143
 - use of, 142
- nitric oxide donors for pre-eclampsia prevention, 110, 310, 338
- nitric oxide production, 148
- nitroglycerin infusion, 139
- nitrous oxide/oxygen, 192
- non-alcoholic steatohepatitis, pre-existing hypertension and, 41
- non-depolarising muscle relaxants, 197
- non-pre-eclampsia glomerular disease, persistent proteinuria and, 20
- non-steroidal anti-inflammatory drugs, 203

- obesity,
 - and anaesthesia, 187
 - bariatric surgery for, 224
 - blood pressure changes with, 2
 - choice of cuff size, 3
 - dietary changes for pre-eclampsia prevention, 107
 - dose of MgSO₄ and, 146
 - pre-existing hypertension and, 41
 - weight loss in, 123
- oedema,
 - laryngeal, 188
 - of airway, 196
 - pre-eclampsia definition and, 37
- oestradiol, 175
- oligohydramnios, 45, 69
 - induction of labour and, 175
- oliguria, 135
 - and anaesthesia, 188
 - pre-eclampsia risk, 39
- online calculator, 48
 - for pre-eclampsia risk, 39
- ophthalmic artery, Doppler imaging, 40
- opioids,
 - for parenteral analgesia, 193
 - hypertensive response to intubation, 197
 - intrathecal, 204
 - intravenous, 203
 - oral, 203
- orthostasis, 20
- out-of-hospital care, 125
- outpatient care, 125
- oxidative stress, 86, 104
- oxygen saturation,
 - for pre-eclampsia, 42
 - pre-eclampsia risk, 39
- oxytocin, 176, 201
 - impact on anaesthesia, 190, 190

- pain,
 - analgesia in labour, 191
 - control of, 202

- pain *continued*
 physiological effects of, 202
 postoperative management, 202–4
- PAPP-A, 86, 88, 89
 as part of multivariable analysis, 88, 89, 90
- paracetamol, 203
- parenteral analgesia, 192
- parity,
 as a risk factor, 80
 blood pressure changes with, 2
 pre-eclampsia risk, 39
 timing of delivery, 171
- paternal risk factors, 78
- patient advocacy, 45
- patient perspective in pre-eclampsia, 45
- patient-controlled analgesia, 193, 203
- PELICAN study, 44
- periodontal disease, 81, 110, 314
- persistent proteinuria, 20
- pethidine, 193
- phaeochromocytoma, 43
- phenotype for pre-eclampsia, 44
- phenylephrine, 198
- phenytoin, cf MgSO₄, 144
- physical activity and pre-eclampsia, 124
- phytonutrient supplementation, 109
- placental abruption, 39
 risk in pre-existing hypertension, 35
 timing of delivery in chronic hypertension, 174
- placental growth factor, 44, 86, 86, 88, 89
 as part of multivariable analysis, 89
 ratio to sFlt-1, 87
 role in pre-eclampsia, 36
- placental perfusion, 86
- plasma volume expansion, 133
- platelet count,
 tests for pre-eclampsia, 42
 timing of delivery, 171
- platelet distribution width, 39
- platelet transfusion, 147
- podocyturia as a predictor, 84
- point-of-care paper-based microfluidic diagnostic stamps, 28
- policy briefs,
 for antihypertensive therapy, 368
 for blood pressure measurement, 238
 for MgSO₄ treatment, 369
 for postpartum care, 412
 for proteinuria, 247
 sample policy brief for blood pressure measurement, 238
- position for blood pressure measurement, 3
- post-traumatic stress disorder, 45, 201
 risks after pre-eclampsia, 221
- postdural puncture headache, 195, 200, 201
- posterior reversible leukoencephalopathy syndrome, 39
- postpartum care, 215–27
 GRADE evaluation of best practice points, 410
 international guidelines, 414–19
 policy brief, 412
 priorities for in under-resourced settings, 226
- potassium, increased intake, 123
- poverty and pre-eclampsia prevention, 110
- PP-13 as part of multivariable analysis, 88
- pravastatin, 148
- prazosin, 143
- pre-eclampsia,
 adverse conditions of, 39
 adverse conditions that define it, 38
 biomarkers for, 44
 choice of anaesthesia for, 199
 choice of antihypertensive treatment in, 136
 choice of neuraxial anaesthesia for, 199
 classification, 34
 definitions, 35, 37, 266–73
 diet and, 123–4
 early-onset, causes, 36
 effect on offspring health, 144
 estimates for incidence, 64
 familial risk factors, 76–8
 fluid management in, 133–5
 fluid restriction, 135
 health issues in offspring, 218
 imitators of, 43
 impact of classification, 52
 indications for delivery, 169
 international clinical guidelines for prediction, 288–9
 late-onset, causes, 37
 late-onset vs. early-onset incidence, 65
 long-term maternal health after, 218–21
 management of, 134
 maternal testing in suspected, 41, 42
 MgSO₄ use for, 144
 model for, 36
 novel therapies for, 148
 origins, 35
 paediatric neurodevelopment after, 217
 paternal risk factors, 78
 performance of predictive tests for pre-eclampsia, 277–87
 phenotypes of, 44
 planning future pregnancies after, 217
 post-traumatic stress after, 45
 postpartum work up after, 217
 prediction, 82–90
 predictors for, 75–92
 prevention, 101–13
 best practice points, 340–3
 in intermediate-risk women, 105
 previous as a risk factor, 80
 recognition of risks, 169
 risk factors for, 75–92

- risk markers for, 77
- risks of general anaesthesia in, 196
- severe,
 - definition, 37, 171, 266–73
 - risks of expectant care, 169
- systemic effects on anaesthesia, 188–9
- trials and reviews of interventions for prevention, 291–315, 316–39
- pre-existing hypertension,
 - classification, 34
 - definition, 35
 - investigations for, 41
 - postpartum treatment, 215
 - screening for after pre-eclampsia, 217
- pre-existing medical conditions, 79
- pre-gestational diabetes, 79
- prediction, 82–90
 - multivariable analyses, 87–90
 - priorities for, 92
 - univariable analyses, 83–7
 - blood pressure, 83
 - calcium, 84
 - laboratory markers, 85
 - podocyturia, 84
 - proteinuria, 83
- predictors,
 - angiogenic factors, 86
 - endothelial dysfunction tests, 86
 - for adverse outcomes, 171
 - for pre-eclampsia, 75–92
 - maternal characteristics plus biomarkers, 88
 - performance of predictive tests for pre-eclampsia, 277–87
 - warning signs and symptoms, 127
- pregnancy,
 - balancing prolongation with delivery risk, 167
 - choice of BPM device for, 5
 - complications in offspring after pre-eclampsia, 218
 - planning future pregnancies, 217
 - recommended weight gain during, 124
 - trials and reviews of interventions for prevention of pre-eclampsia, 291–315, 316–39
- pregnancy interval as a risk factor, 80
- pregnancy-induced hypertension and confusion, 35
- prematurity, complications associated with, 169
- preterm delivery,
 - complications associated with, 169
 - risk in pre-existing hypertension, 35
- prevention,
 - in women at low-risk, 101–5
 - of pre-eclampsia, 101–13
 - trials and reviews of interventions for prevention of pre-eclampsia, 291–315, 316–39
- primipaternity, 81
- priorities in urine testing, 27, 28
- priorities for future research,
 - biomarkers, 51
 - for anaesthesia and analgesia, 207
 - for classification of pre-eclampsia, 52
 - for diet lifestyle and place of care, 130
 - for epidemiology, 69
 - for fluid, drugs and transfusions, 156
 - for hypertension identification, 13
 - for prevention of pre-eclampsia, 114
 - for risk factors and predictors, 91
 - in proteinuria, 29
 - postpartum care, 227
 - precision medicine, 52
 - timing and mode of delivery, 179
- priorities for under-resourced settings,
 - diagnosis of hypertensive disorders of pregnancy, 47
 - for anaesthesia and analgesia, 205
 - for classification of pre-eclampsia, 47
 - for diet lifestyle and place of care, 129
 - for fluid drugs and transfusions, 154
 - for risk factors and predictors, 91–2
 - hypertension identification, 12
 - in proteinuria, 27
 - postpartum treatment, 225
 - timing and mode of delivery, 177
- prioritisation of urine testing, 28
- proangiogenic factors, 86
- probiotics, 103
- prolonged labour, 76
- prolonged neuromuscular block, 197
- prophylaxis, 75
- propofol, 197
- prostacyclin, 137
- prostaglandin E₂, 175
- prostaglandin precursors, 104, 304
 - for pre-eclampsia prevention, 109, 330
- proteinuria,
 - and anaesthesia, 188
 - antihypertensive use and, 141
 - as a predictor, 83
 - best practice points, 250
 - causes of, 19, 20
 - cost considerations for testing, 26
 - cost-effective testing, 26
 - definition of significant proteinuria, 26
 - detection of, 20
 - dipstick testing, 21
 - heat coagulation test, 22
 - international guidelines for diagnosis, 251–3
 - measurement of, 19–29
 - in antenatal care, 9
 - methods of assessment, 248
 - normal levels, 19
 - persistent, 20
 - policy brief, 247
 - prioritisation of urine testing, 28
 - screening for, 20

- proteinuria *continued*
 self-test, 27
 spot albumin : creatinine ratio, 25
 spot protein : creatinine ratio, 24
 sulfosalicylic acid testing, 23
 timed urine collection, 26
 timing of delivery, 171
 transient, 19
- prothrombin gene mutation, 79
- proton pump inhibitors, 150
- pulmonary artery catheters, 191
- pulmonary oedema, 39, 135
 and anaesthesia, 188
- pyridoxine, 105, 109
- rainy season and pre-eclampsia trends, 66
- relative rise in blood pressure, 3
- relaxation techniques, 141
- remifentanyl, 193, 197
- renal disease,
 and anaesthesia, 187
 exacerbation postpartum, 216
 pre-existing and proteinuria, 20
 risk after pre-eclampsia, 220
- renal function, 86
- renal parenchymal disease, 35
- resistant hypertension, definition, 37
- respiratory alkalosis, 191
- respiratory failure, 201
- rest,
 bed rest, 109, 125
 increased, 109
- restricting therapy, 145
- resuscitation,
 after parenteral analgesia, 193
 equipment for, 185
 essential equipment for, 186
 maternal, 186
 neonatal, 186
- retinal detachment, 68
- risk factors,
 age, 78
 balancing pregnancy prolongation with delivery risk, 167
 demographic, 78
 ethnicity, 78
 familial, 76–8
 for cardiovascular disease after pre-eclampsia, 218, 219
 for hypertensive disorders of pregnancy, 66
 for pre-eclampsia, 75–92
 identification of for timing of delivery, 171
 identification of women at risk in LMICs, 75
 laboratory markers, 85
 past medical history, 79
 paternal, 81
 performance of predictive tests for pre-eclampsia, 277–87
 pregnancy-associated, 80
 risk markers for pre-eclampsia, 77
 screening for cardiovascular risk factors, 222
 road infrastructure, 126
- S100B, 45, 51
- S-nitrosoglutathione, 148, 149
- salt, reduced intake, 107, 123, 124
 pre-eclampsia prevention and, 102
- sample policy brief for blood pressure measurement, 238
- SCOPE Consortium cohort, 88
- Scottish paradigm for antenatal care, 33
- screening,
 cost-effectiveness in proteinuria, 26
 for cardiovascular risk factors, 222
 for pre-existing hypertension after pre-eclampsia, 217
 for proteinuria, 20
 for thrombophilia after pre-eclampsia, 217
- seizures and proteinuria, 20
- selenium supplementation, 105, 109
- sepsis,
 proteinuria and, 20
 risk, 76
- serum chemistry for pre-eclampsia, 43
- settings,
 appropriate levels of care, 169
 best practice points for place of care, 345
 choice of device for, 6
 community-based care, 126
 community-based engagement, 127
 facility vs. community, 48
 for blood pressure measurement, 5
 home care, 125
 hospital day units, 125
 international guidelines for recommendations on place of care, 346–8
 out-of-hospital care, 125
 outpatient care, 125
 postpartum care in community, 226
 transport to facility, 126
- severe hypertension, *see* hypertension, severe
- sFlt-1, 44
 levels in multiple pregnancy, 80
 ratio to PlGF, 87
- shivering,
 cuff size and, 198
 with epidural anaesthesia, 200
- sildenafil, 148
- single nucleotide polymorphisms,
 MTHFR, 79

- prothrombin, 79
- single-shot spinal analgesia, 195
- small for gestational age,
 - antihypertensive use and, 140
 - interventionist care at 24⁰–33⁶ weeks, 172
 - risk in pre-eclampsia, 35
 - risk in pre-existing hypertension, 35
- smartphone technology, links to BPM devices, 8
- smoking,
 - as a risk factor, 82
 - cessation, 306
 - pre-eclampsia prevention and cessation, 104, 330
- snails, 105
- socioeconomic status, 82
- sodium intake, 124
- solar power for BPM devices, 8
- sperm exposure, 81
- spinal anaesthesia,
 - vs. epidural in pre-eclampsia, 199
 - vs. general anaesthesia in pre-eclampsia, 199
- spinal neuroanatomy, 187
- spot albumin : creatinine ratio, 25
- spot protein : creatinine ratio, 24
- standardising care, 151
- stature, 79
- stillbirth, 39
 - antihypertensives and, 143
 - incidence, 69
 - risk and proteinuria, 26
 - risk in pre-existing hypertension, 35
 - timing of delivery in chronic hypertension, 174
- stress,
 - management and pre-eclampsia, 124
 - post-traumatic, 45
 - reduction, 112
- stroke, 68, 196
 - incidence, 68
 - risk after pre-eclampsia, 220
 - risk markers for, 135
 - thrombocytopenia, 189
- subarachnoid haemorrhage, 189
 - proteinuria and, 20
- sulfosalicylic acid testing, 23
- supplementation,
 - calcium, 75
 - folate-containing multivitamins, 103
 - high-protein, 102
 - isocaloric protein, 102
 - magnesium, 103
 - micronutrients, 103
 - phytonutrients, 104
 - protein/energy supplements in undernourished women, 102
 - pyridoxine, 104
 - selenium, 105, 109
 - vitamins, 104, 105
- zinc, 104
- surveillance, for risk factors, 75
- symphysis–fundal height, assessment of gestational age, 168
- systemic lupus erythematosus, 216
- tablet technology, links to BPM devices, 8
- Tamm–Horsfall protein, 19
- taurine as part of multivariable analysis, 89
- temporal trends, 65
- thiazide diuretics, 142, 308
 - pre-eclampsia prevention and, 104, 352
- thiopental, 197
- three-delay model, 126
- thrombocytopenia, 176
 - and anaesthesia, 189
- thromboembolic disease, interventionist care, 173
- thrombophilias,
 - as a risk factor, 79
 - screening for after pre-eclampsia, 217
- thromboprophylaxis, 148
 - postpartum, 216
- thrombosis, 43
- thrombotic thrombocytopenic purpura, 148
- thrombotic thrombocytopenic purpura–haemolytic uraemic syndrome, 43, 216
- thyroid-stimulating hormone, elevated, 220
- thyroxine-binding prealbumin, 19
- timed urine collection, 26
- timing of delivery, 167
 - at 24⁺⁰–33⁺⁶ weeks, 172
 - at 34⁺⁰–36⁺⁶ weeks, 173
 - at 37⁺⁰–42⁺⁰ weeks, 174
 - at <24⁺⁰ weeks, 172
 - consideration of pre-eclampsia severity, 171
 - gestational age at diagnosis and, 170
 - identification of risk factors and, 171
 - in women with chronic hypertension, 174
 - in women with gestational hypertension, 174
 - in women with pre-existing hypertension, 174
 - predicting adverse outcome, 171
 - priorities for, 178
- tinzaparin, 108
- traditional medicines, 105
- traffic light early warning system, 8
- training,
 - emergency obstetric simulation training, 351–64
 - for health care workers, 10
 - health care workers for blood pressure measurement, 235
 - knowledge translation tools, 409
 - material for health care workers, 407–8
 - of health workers, 67
 - pre-eclampsia prevention and training of health care workers, 110

THE FIGO TEXTBOOK OF PREGNANCY HYPERTENSION

- tramadol, 193
- transferrin, 19
- transfusion,
 - GRADE evaluation of best practice points, 365–7
 - international clinical guidelines for, 370–81
 - use in HELLP syndrome, 147
- transient hypertensive effect, classification, 34
- transient proteinuria, 19
- transport,
 - delays and mortality, 67
 - delays in, 126
 - road infrastructure, 126
 - to care facility, 126
- transthoracic echocardiography, 191
- transversus abdominis plane blocks, 204
- treatment,
 - delays and mortality, 67
 - delays in, 126
 - standardising care, 151
- treatment postpartum, 215–27
- triage,
 - delays and mortality, 67
 - delays in, 126
- trisomy 21, 85
- tubular disease, persistent proteinuria and, 20
- tubular proteins, 19

- ultrasound,
 - assessment of gestational age, 168
 - availability in LMICs, 168
- umbilical artery, end-diastolic flow in, 45
- under-resourced settings,
 - antenatal care in, 8
 - assessment of gestational age in, 168
 - blood pressure measurement in, 7–10
 - heat coagulation test for proteinuria in, 22
 - road infrastructure, 126
 - traffic light early warning system, 8
 - transport to facility in, 126
- undernourished women, 102
- urapidil, 137
- uric acid,
 - pre-eclampsia risk, 39, 39, 40
 - serum levels, 43
- urinary dipsticks,
 - automated testing of, 22
 - visual interpretation of, 21
- urinary sediment, 216
- urine testing,
 - for pre-eclampsia, 42
 - for proteinuria, 21–6

- uterine artery, 43
 - as part of multivariable analysis, 90
 - Doppler imaging, 40, 84
 - Doppler imaging and delivery, 175
 - pulsatility index, 88, 89
- uterine rupture, 175

- vaginal delivery at 34⁺⁰–36⁺⁶ weeks, 174
- vascular resistance, 86
- vasopressors, 198
- verbal ability, 144
- visual disturbances and pre-eclampsia risk, 39
- visual interpretation of urinary dipsticks, 21
- visual symptoms, timing of delivery, 171
- vitamin A, 105, 109
- vitamin C, 308
 - deficiency and risk, 82
 - pre-eclampsia prevention and, 104, 109, 332
- vitamin D,
 - deficiency and risk, 82
 - pre-eclampsia prevention and, 105
- vitamin E, 308
 - deficiency and risk, 82
 - pre-eclampsia prevention and, 104, 109, 332
- wall chart,
 - hypertension treatment, 349
 - MgSO₄ treatment, 350
- weight,
 - extremes of and pre-eclampsia risk, 39
 - recommended weight gain during pregnancy, 124
- weight gain,
 - between pregnancies, 108
 - pre-eclampsia definition and, 37
- white blood cell count for pre-eclampsia, 42
- white coat hypertensive effect, classification, 34
- white-coat effect, 40
- WHO analgesic ladder, 202
- WHO prediction test, 83
- WHO recommendations, for antenatal care, 9
- work, physically demanding, 109
- workload,
 - reduction, 109
 - role in pre-eclampsia, 124
- wound infiltration, 204

- yoga, 112

- zinc supplementation, 104, 109







